» Articles » PMID: 33968439

New Insights in the Pathology of Peritoneal Surface Malignancy

Overview
Date 2021 May 10
PMID 33968439
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Pathology is central to the management of peritoneal surface malignancy. This article highlights some recent advances that have had an impact on patient management or could do so in the near future. Malignant peritoneal mesothelioma, particularly the epithelioid subtype, is amenable to radical therapy in selected cases, and factors such as ki67 proliferation index, expression of BAP1 and mutation in show promise as prognostic indicators. Our understanding of multicystic mesothelioma has improved in recent years; it is a true neoplasm for which surgery may be indicated. Serous carcinomas involving the peritoneum are now known to originate from tubal epithelium. They are of two distinct types, high grade and low grade, which are now recognized as different neoplasms with distinctive features, oncogenesis and behavior. Pseudomyxoma peritonei (PMP) is an unusual condition that usually arises from an appendiceal mucinous neoplasm. Recent consensus in the classification and nomenclature of these lesions is discussed, including the distinction between low grade and high grade appendiceal mucinous neoplasms (HAMN), and the diagnostic criteria for appendiceal adenocarcinoma. PMP is divided into four prognostic groups: acellular mucin, low grade mucinous carcinoma peritonei, high grade mucinous carcinoma peritonei, and high grade mucinous carcinoma peritonei with signet ring cells. The pseudomyxoma microbiome is a promising area for clinical intervention but has been the subject of little research activity. Goblet cell adenocarcinoma (previously known as 'goblet cell carcinoid') is a distinctive type of appendiceal adenocarcinoma. Its behavior correlates with histologic features, but no general consensus for classification has been reached.

Citing Articles

Case report: Intra-abdominal inflammatory myofibroblastic tumor with mucinous features: a case of rapid recurrence and dissemination post-surgery.

Li X, Li J, Liang C, Zou Q Front Oncol. 2025; 14:1517710.

PMID: 39871941 PMC: 11770369. DOI: 10.3389/fonc.2024.1517710.


Extent of peritoneal metastases from colorectal cancer is not associated with changes in thrombin generation or fibrinolysis.

Lundbech M, Krag A, Iversen L, Brandsborg B, Hvas A Pleura Peritoneum. 2024; 9(4):149-154.

PMID: 39712293 PMC: 11661465. DOI: 10.1515/pp-2024-0009.


Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.

Gibson J, Pengelly R, Mirandari A, Boukas K, Stanford S, Cecil T Cancer Med. 2024; 13(20):e70340.

PMID: 39435876 PMC: 11494485. DOI: 10.1002/cam4.70340.


Metastasis-associated fibroblasts in peritoneal surface malignancies.

Ramos C, Gerakopoulos V, Oehler R Br J Cancer. 2024; 131(3):407-419.

PMID: 38783165 PMC: 11300623. DOI: 10.1038/s41416-024-02717-4.


Intratumor microbiota as a novel potential prognostic indicator in mesothelioma.

Pentimalli F, Krstic-Demonacos M, Costa C, Mutti L, Bakker E Front Immunol. 2023; 14:1129513.

PMID: 36999042 PMC: 10043377. DOI: 10.3389/fimmu.2023.1129513.


References
1.
Brandl A, Westbrook S, Nunn S, Arbuthnot-Smith E, Mulsow J, Youssef H . Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open. 2020; 4(2):260-267. PMC: 7093780. DOI: 10.1002/bjs5.50256. View

2.
Lai J, Zhou Z, Tang X, Gao Z, Zhou J, Chen S . A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. Int J Mol Sci. 2016; 17(5). PMC: 4881561. DOI: 10.3390/ijms17050739. View

3.
Sethna K, Mohamed F, Marchettini P, Elias D, Sugarbaker P . Peritoneal cystic mesothelioma: a case series. Tumori. 2003; 89(1):31-5. DOI: 10.1177/030089160308900107. View

4.
Roxburgh C, Fenig Y, Cercek A, Shia J, Rassam R, Paty P . Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Ann Surg Oncol. 2018; 26(1):118-124. PMC: 6339600. DOI: 10.1245/s10434-018-7003-7. View

5.
Amin W, Linkov F, Landsittel D, Silverstein J, Bashara W, Gaudioso C . Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2019; 7:1184. PMC: 6198263. DOI: 10.12688/f1000research.15512.3. View